© 2023 MJH Life Sciences and Urology Times. All rights reserved.
© 2023 MJH Life Sciences™ and Urology Times. All rights reserved.
January 11, 2023
“The takeaway from that talk was that it's critically important to review drug plan options, particularly if the patient's on a high-cost drug,” says Kelly L. Stratton, MD, FACS.
January 09, 2023
“I think [it was a] great opportunity to catch up on what is going on with PSMA-PET and theranostics and then also understand that that landscape will change over the near future,” says Kelly L. Stratton, MD, FACS.
December 28, 2022
“Perspectives on testosterone therapy and its use as it pertains to prostate cancer have certainly progressed over [the] years,” Diana Magee, MD, MPH, MSc.
December 19, 2022
“This study highlights how treatment remains influenced by where you live,” Diana Magee, MD, MPH, MSc.
December 08, 2022
“It's a really simple tool to predict your out-of-pocket costs,” says Benjamin Pockros, MD, MBA, of Medicare Plan Finder.
December 06, 2022
The phase 3 CAPTAIN trial was launched following the pivotal TACT trial, which showed that TULSA provided durable disease control with low toxicity at 3 years’ follow-up in men with localized prostate cancer.
December 05, 2022
Bipolar androgen therapy is being explored in trials with enzalutamide (Xtandi), olaparib (Lynparza), and nivolumab (Opdivo), explains Laura Sena MD, PhD.
December 02, 2022
“This is different from other standard-of-care therapies for prostate cancer because usually we are inhibiting androgen receptor (AR) activity and here we’re actually stimulating AR,” explained Laura Anne Sena, MD, PhD.
Specificity was between 93% to 97% and exceeded the threshold across all readers.
“The outcomes were similar between those who had normal or above, or below normal testosterone levels at baseline," said Kelly L. Stratton, MD.